Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD19 PARs
- Development stage
- Preclinical
- Lead developer
- Tychon Biosciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Anti-CD19 PARs is an investigational **PAR-T cell therapy** being developed by Tychon Biosciences for CD19-positive hematologic malignancies including leukemia and lymphoma. The program uses prosthetic antigen receptor technology in which protein-based, chemically self-assembling nanorings link a patient's T cells to CD19-expressing tumor cells without genetic engineering, representing a non-CAR-T cellular immunotherapy approach. The candidate remains in discovery-stage preclinical development and is intended as an antineoplastic immunotherapy for B-cell malignancies.
- Other names
- CD19 PARsCD-19 PARsCD 19 PARsanti-CD19 PARsanti-CD-19 PARsanti-CD 19 PARsPAR-T anti-CD19CD19-targeted PAR-T therapyCD-19-targeted PAR-T therapyCD 19-targeted PAR-T therapyCD19 PAR-T cell therapyCD-19 PAR-T cell therapyCD 19 PAR-T cell therapy
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on Anti-CD19 PARs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD19 PARs.